{"success":true,"data":{"pressRelease":{"id":"167255","rtpr_id":"nGNX2pgrTB-20261013","ticker":"IBIO","exchange":"NASDAQ","all_tickers":["IBIO"],"title":"iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy","author":"Globe Newswire","published_at":"2026-10-13T11:00:01.770Z","article_body":"In an eight-week obese NHP study, lean mass made up 6% of weight lost with\nIBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide\nalone\n\niBio expects to start first-in-human trials of IBIO-610 in first half of 2027\n\nSAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a\nclinical-stage biotechnology company developing long-acting antibody\ntherapeutics for obesity, cardiometabolic and cardiopulmonary diseases,\nhighlighted preclinical body-composition data from its obese non-human primate\n(NHP) study evaluating IBIO-610, potentially a first-in-class Activin E\nantibody candidate, alone and in combination with semaglutide, a GLP-1\nreceptor agonist used to treat obesity. The data\n(https://www.globenewswire.com/Tracker?data=yEdeC5mLNK166CnvDPcXOqV2XmIlfWdy5CU-owZLgwIi1GS7dlr6zEjWgUMOyyZeDTfUoLlSJivqRFRS648kZ9X7DcRr_X6F9OCjHi8BUJawphUx4YOrfRU4WIR8ID9wLODB6YG6kA3v3R-ikjYygPqt0zgd093wSA9hOl-exKt3uD2NVucfGl7ZW-TpayXBETmWDzXSo-6C5XV9Y2rstU6MTM6uUKtp8PmRQDf3xmE=)\nwere discussed in an oral presentation at the European Association for the\nStudy of Diabetes (EASD) Annual Meeting on October 1, 2026.\n\n“While GLP-1 therapies have transformed obesity care, patients still need\nadditional options to improve the quality of weight loss,” said Martin\nBrenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of\niBio. “In this NHP study, IBIO-610 delivered durable, near-complete\ninhibition of active Activin E, and when combined with semaglutide, nearly all\nobserved weight loss came from fat. We plan to begin first-in-human studies in\nthe first half of 2027. Our focus is on translating this biology into a\npotential new therapeutic option for patients living with obesity and\ncardiometabolic disease.”\n\nAdditional analysis of the eight-week obese NHP study (n=6 per group) further\ncharacterized the potential for IBIO-610 to support muscle preservation when\ncombined with semaglutide. At week 8, fat accounted for 93% of the weight lost\nby NHPs given a single dose of IBIO-610 alongside twice-weekly semaglutide,\ncompared with 77% for NHPs given semaglutide alone.\n\nThese results build on previously reported data\n(https://www.globenewswire.com/Tracker?data=yEdeC5mLNK166CnvDPcXOli0_ivHvFICwBiHcspYG4F4GnMADRTibn6aT_tlg13DdJandnaH5MxpGov0QXygAKufLdBbzTPM3pT-wQuqdqzxfH7L86r_yyb6qMo6cKi6ZEJ1Q7R58Ax7nXp6hdUNvXLeH8uvMBcVmcmomFTYh2v03BTGciQDwLxYiM3twIR-u-IcE1uXZBklS0CmOQpikzQcSiIjwFKyIZuKDdVZ9tzZvgdgb4dd2qnncAakCA3OfTnwZPUPGoPlPSe-yjyrF8Iza2XPPnhJPGxTE2mL3iU=)\nfrom this NHP study, in which IBIO-610 demonstrated a 97% reduction in serum\nlevels of active Activin E at week 8 following a single intravenous dose. The\nstudy also found that IBIO-610 had a 33.2-day half-life in NHPs, with a\nprojected human half-life potentially supporting twice-yearly dosing.\n\nAbout iBio, Inc.\n\niBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting\nantibody therapeutics for obesity, cardiometabolic and cardiopulmonary\ndiseases, cancer, and other hard-to-treat diseases. Combining advanced\nantibody engineering with AI-driven discovery, iBio is advancing a\ndifferentiated pipeline designed to deliver sustained therapeutic effects and\naddress significant unmet medical needs. iBio’s mission is to transform drug\ndiscovery, accelerate development timelines, and unlock new possibilities in\nprecision medicine.\n\nFor more information, visit www.ibioinc.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Up0s2fFCyyXdra5kB0hxi5TRfyAjMXhWjwkmd9qrahiViHgoBjlLL0TjspUsNyY1lf1-AkJEnnfkg-OtmqqzdbG8NWtX48BhbK1-MrIR_9TrhN5haz0vlolHBVuEUfAvKnyK18OEOy6kZcHFH2HgfbTqtDFYLV_wZwRk1Q5cqria4gIiX2sZyChzHNUsCEawFcLlH7gWjVVW-ZZ_Is-QfkInLet_dB9-RYNWNxlfzi7sXXsBTrvmvN7kEHfUdvgM9XhFU9eTAgztXQgE7OFbjYhRZTIGyHkhKbyr8M9N6y5MhRNZcPXFdSNBvh5VfczaYVeeORT7tH_M2M6pqBebZGclOO5CJjgJWK-gtmuT4f2sYSdUe9tKJYKcVKZpteRblv8hPx-4Ucc2nRLsNf4iK60PDmBXsrAn1kvuwu232HaWMHXtLB99sIuLC7qhz-4QupHNIJVjnxd5JX8RBE1m3h1XjxZiOEuJDHOrZls3DVs6cDt5hnIrNuTX4gRqmjRlPN8QToRWK8vpOwbFyep9rQclhRHd_LwkBmtGLyK1CsdgsnKbRETSQU9rG1i9-WWgCvHdFZZiuClhv8RvQZs8YHNeRSOMxSXqPRK2Gz4CO8g1g8OB8wqjp2_uYrn-U97TF38GZWhbs83nTsRIHGNx4ARMblsa28FKjTCyn0QSIpiQQLm5lD9SwGn7eWANvuu6CmIE2btlYFZS9ShPN-MC28qssoVkWJaSDqnpL3OlXa41LcsO_2GltfhWPiW93dghoy1ERWnUHGAfYrYB8RP6Ea9lesGXTGX66s_E_x5UPwOkTn5AmsFjIRZqHX-0wEX2HVVZz3FZ_lD-3x21fy9BrxRFZT3U9jxHfqzPlH4j40kC7Vf0YZ-3ff5ifshBdBgDLW6qddXzAIJFpu6e4JbhO-OGBg4z18l6xecqQyXZPpBf8lnNj4aCxoNGz4l2FwfziyiD0zKoAVugEF6H3Yu9y7epiejlgyCkMMHLtB1tnxLOUKsV3LVDrpD6S9zgMXMXW1GHMiUgAkpiFky1sezki4osRIWHkRRs4BXZAPuI7WOOBynjRpS9a6KJ_Xn_hMltyOgt_7KaGH8HdB8CNi2SppG4HqkSo1Vo9gVE8S_0ChVwr9xK6MBoS8dLb-WfmktmIJ1gMjU7_9P-97bFFPh-nF75yDWrF7HsI2InAwq9yewUfZtwzutkp78pOFQAOcMLU3cKlQ3aMtfPkZ-8y0QAOg_AGmQl6ZuAXecIbBQPaoj8CU_J5sOETeD-sgtcdXTLUEMEthE8Xxs-kUv9ndGUO1KhuxKTLTCL9NhMOOM4HmhyatQrCVOW8CXcqIRX4HBB1eo-o58CVoqG3QGibaZXsMapt5x24PZOXd60nbB2iZzpOqNdqqcwJaPMcoXqzx-7Y5QKu1WbndKyfOSu3aq3m4r57jvRSFpJM_M562KrBk2e0tGQrUJqAaSb-S9CUYa4vrYMT75U5FpQ7GwGMC7c8q6FJrWGIZWUaTM0nBjxBTva9QlEIB2LFXJKydHbtWFlx-912ZGFUM_KlGlWcOAzc5HwIoK7eRCy3k-05LmubL-YgkDdjr0NSD790gTeIkGaiigctXoRau_Yf1l7kQ8dBA==).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe federal securities laws, including statements about IBIO-610’s potential\nto preserve muscle in combination with semaglutide, a GLP-1 receptor agonist\nused to treat obesity; IBIO starting first-in-human trials of IBIO-610 in the\nfirst half of 2027; translating the biology into a potential new therapeutic\noption for patients living with obesity and cardiometabolic disease; IBIO-610\nhaving a projected human half-life potentially supporting twice-yearly dosing;\nand iBio’s transforming drug discovery, accelerate development timelines,\nand unlock new possibilities in precision medicine. These statements reflect\niBio’s current expectations and assumptions and are subject to risks and\nuncertainties that could cause actual results to differ materially, including\nthe possibility that findings in NHPs will not be replicated in humans;\nIBIO’s ability to start first-in-human trials of IBIO-610 in the first half\nof 2027, risks of product development and regulatory approval, and the other\nrisks described in iBio’s filings with the Securities and Exchange\nCommission, including its Annual Report on Form 10-K for the year ended June\n30, 2026. Forward-looking statements speak only as of the date of this\nrelease. iBio undertakes no obligation to update them except as required by\nlaw.\n\nInvestor Contact\nMatt Beck\nastr partners\nmatthew.beck@astrpartners.com\n(917) 415-1750\n\nMedia Contact\nJason Braco, Ph.D.\nValence Communications\njason@valencecomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c472b1f4-0d21-4a83-b703-3214f1faebbc)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2pgrTB-20261013","title":"iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy","author":"Globe Newswire","ticker":"IBIO","created":"2026-10-13T11:00:01.770Z","tickers":["IBIO"],"exchange":"NASDAQ","article_body":"In an eight-week obese NHP study, lean mass made up 6% of weight lost with\nIBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide\nalone\n\niBio expects to start first-in-human trials of IBIO-610 in first half of 2027\n\nSAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a\nclinical-stage biotechnology company developing long-acting antibody\ntherapeutics for obesity, cardiometabolic and cardiopulmonary diseases,\nhighlighted preclinical body-composition data from its obese non-human primate\n(NHP) study evaluating IBIO-610, potentially a first-in-class Activin E\nantibody candidate, alone and in combination with semaglutide, a GLP-1\nreceptor agonist used to treat obesity. The data\n(https://www.globenewswire.com/Tracker?data=yEdeC5mLNK166CnvDPcXOqV2XmIlfWdy5CU-owZLgwIi1GS7dlr6zEjWgUMOyyZeDTfUoLlSJivqRFRS648kZ9X7DcRr_X6F9OCjHi8BUJawphUx4YOrfRU4WIR8ID9wLODB6YG6kA3v3R-ikjYygPqt0zgd093wSA9hOl-exKt3uD2NVucfGl7ZW-TpayXBETmWDzXSo-6C5XV9Y2rstU6MTM6uUKtp8PmRQDf3xmE=)\nwere discussed in an oral presentation at the European Association for the\nStudy of Diabetes (EASD) Annual Meeting on October 1, 2026.\n\n“While GLP-1 therapies have transformed obesity care, patients still need\nadditional options to improve the quality of weight loss,” said Martin\nBrenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of\niBio. “In this NHP study, IBIO-610 delivered durable, near-complete\ninhibition of active Activin E, and when combined with semaglutide, nearly all\nobserved weight loss came from fat. We plan to begin first-in-human studies in\nthe first half of 2027. Our focus is on translating this biology into a\npotential new therapeutic option for patients living with obesity and\ncardiometabolic disease.”\n\nAdditional analysis of the eight-week obese NHP study (n=6 per group) further\ncharacterized the potential for IBIO-610 to support muscle preservation when\ncombined with semaglutide. At week 8, fat accounted for 93% of the weight lost\nby NHPs given a single dose of IBIO-610 alongside twice-weekly semaglutide,\ncompared with 77% for NHPs given semaglutide alone.\n\nThese results build on previously reported data\n(https://www.globenewswire.com/Tracker?data=yEdeC5mLNK166CnvDPcXOli0_ivHvFICwBiHcspYG4F4GnMADRTibn6aT_tlg13DdJandnaH5MxpGov0QXygAKufLdBbzTPM3pT-wQuqdqzxfH7L86r_yyb6qMo6cKi6ZEJ1Q7R58Ax7nXp6hdUNvXLeH8uvMBcVmcmomFTYh2v03BTGciQDwLxYiM3twIR-u-IcE1uXZBklS0CmOQpikzQcSiIjwFKyIZuKDdVZ9tzZvgdgb4dd2qnncAakCA3OfTnwZPUPGoPlPSe-yjyrF8Iza2XPPnhJPGxTE2mL3iU=)\nfrom this NHP study, in which IBIO-610 demonstrated a 97% reduction in serum\nlevels of active Activin E at week 8 following a single intravenous dose. The\nstudy also found that IBIO-610 had a 33.2-day half-life in NHPs, with a\nprojected human half-life potentially supporting twice-yearly dosing.\n\nAbout iBio, Inc.\n\niBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting\nantibody therapeutics for obesity, cardiometabolic and cardiopulmonary\ndiseases, cancer, and other hard-to-treat diseases. Combining advanced\nantibody engineering with AI-driven discovery, iBio is advancing a\ndifferentiated pipeline designed to deliver sustained therapeutic effects and\naddress significant unmet medical needs. iBio’s mission is to transform drug\ndiscovery, accelerate development timelines, and unlock new possibilities in\nprecision medicine.\n\nFor more information, visit www.ibioinc.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=Up0s2fFCyyXdra5kB0hxi5TRfyAjMXhWjwkmd9qrahiViHgoBjlLL0TjspUsNyY1lf1-AkJEnnfkg-OtmqqzdbG8NWtX48BhbK1-MrIR_9TrhN5haz0vlolHBVuEUfAvKnyK18OEOy6kZcHFH2HgfbTqtDFYLV_wZwRk1Q5cqria4gIiX2sZyChzHNUsCEawFcLlH7gWjVVW-ZZ_Is-QfkInLet_dB9-RYNWNxlfzi7sXXsBTrvmvN7kEHfUdvgM9XhFU9eTAgztXQgE7OFbjYhRZTIGyHkhKbyr8M9N6y5MhRNZcPXFdSNBvh5VfczaYVeeORT7tH_M2M6pqBebZGclOO5CJjgJWK-gtmuT4f2sYSdUe9tKJYKcVKZpteRblv8hPx-4Ucc2nRLsNf4iK60PDmBXsrAn1kvuwu232HaWMHXtLB99sIuLC7qhz-4QupHNIJVjnxd5JX8RBE1m3h1XjxZiOEuJDHOrZls3DVs6cDt5hnIrNuTX4gRqmjRlPN8QToRWK8vpOwbFyep9rQclhRHd_LwkBmtGLyK1CsdgsnKbRETSQU9rG1i9-WWgCvHdFZZiuClhv8RvQZs8YHNeRSOMxSXqPRK2Gz4CO8g1g8OB8wqjp2_uYrn-U97TF38GZWhbs83nTsRIHGNx4ARMblsa28FKjTCyn0QSIpiQQLm5lD9SwGn7eWANvuu6CmIE2btlYFZS9ShPN-MC28qssoVkWJaSDqnpL3OlXa41LcsO_2GltfhWPiW93dghoy1ERWnUHGAfYrYB8RP6Ea9lesGXTGX66s_E_x5UPwOkTn5AmsFjIRZqHX-0wEX2HVVZz3FZ_lD-3x21fy9BrxRFZT3U9jxHfqzPlH4j40kC7Vf0YZ-3ff5ifshBdBgDLW6qddXzAIJFpu6e4JbhO-OGBg4z18l6xecqQyXZPpBf8lnNj4aCxoNGz4l2FwfziyiD0zKoAVugEF6H3Yu9y7epiejlgyCkMMHLtB1tnxLOUKsV3LVDrpD6S9zgMXMXW1GHMiUgAkpiFky1sezki4osRIWHkRRs4BXZAPuI7WOOBynjRpS9a6KJ_Xn_hMltyOgt_7KaGH8HdB8CNi2SppG4HqkSo1Vo9gVE8S_0ChVwr9xK6MBoS8dLb-WfmktmIJ1gMjU7_9P-97bFFPh-nF75yDWrF7HsI2InAwq9yewUfZtwzutkp78pOFQAOcMLU3cKlQ3aMtfPkZ-8y0QAOg_AGmQl6ZuAXecIbBQPaoj8CU_J5sOETeD-sgtcdXTLUEMEthE8Xxs-kUv9ndGUO1KhuxKTLTCL9NhMOOM4HmhyatQrCVOW8CXcqIRX4HBB1eo-o58CVoqG3QGibaZXsMapt5x24PZOXd60nbB2iZzpOqNdqqcwJaPMcoXqzx-7Y5QKu1WbndKyfOSu3aq3m4r57jvRSFpJM_M562KrBk2e0tGQrUJqAaSb-S9CUYa4vrYMT75U5FpQ7GwGMC7c8q6FJrWGIZWUaTM0nBjxBTva9QlEIB2LFXJKydHbtWFlx-912ZGFUM_KlGlWcOAzc5HwIoK7eRCy3k-05LmubL-YgkDdjr0NSD790gTeIkGaiigctXoRau_Yf1l7kQ8dBA==).\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe federal securities laws, including statements about IBIO-610’s potential\nto preserve muscle in combination with semaglutide, a GLP-1 receptor agonist\nused to treat obesity; IBIO starting first-in-human trials of IBIO-610 in the\nfirst half of 2027; translating the biology into a potential new therapeutic\noption for patients living with obesity and cardiometabolic disease; IBIO-610\nhaving a projected human half-life potentially supporting twice-yearly dosing;\nand iBio’s transforming drug discovery, accelerate development timelines,\nand unlock new possibilities in precision medicine. These statements reflect\niBio’s current expectations and assumptions and are subject to risks and\nuncertainties that could cause actual results to differ materially, including\nthe possibility that findings in NHPs will not be replicated in humans;\nIBIO’s ability to start first-in-human trials of IBIO-610 in the first half\nof 2027, risks of product development and regulatory approval, and the other\nrisks described in iBio’s filings with the Securities and Exchange\nCommission, including its Annual Report on Form 10-K for the year ended June\n30, 2026. Forward-looking statements speak only as of the date of this\nrelease. iBio undertakes no obligation to update them except as required by\nlaw.\n\nInvestor Contact\nMatt Beck\nastr partners\nmatthew.beck@astrpartners.com\n(917) 415-1750\n\nMedia Contact\nJason Braco, Ph.D.\nValence Communications\njason@valencecomms.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c472b1f4-0d21-4a83-b703-3214f1faebbc)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-13T11:00:01.857228101Z","server_sent_at_ms":1791889201857},"received_at":"2026-10-13T11:00:01.908Z","source_url":null},"analysis":{"id":"155567","press_release_id":"167255","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["preclinical data only; NHP findings may not translate to humans","first-in-human trials not expected until H1 2027"],"eventType":"clinical_trial","narrative":"iBio highlighted preclinical data showing IBIO-610, a potential first-in-class Activin E antibody, preserved lean mass in obese non-human primates when combined with semaglutide.\n\nIn the eight-week NHP study (n=6 per group), only 6% of weight lost with the combination was lean mass versus 22% with semaglutide alone; fat made up 93% of weight lost with the combination versus 77% with semaglutide alone.\n\nIBIO-610 also showed a 97% reduction in active serum Activin E and a 33.2-day NHP half-life, with a projected human half-life supporting twice-yearly dosing.\n\nThe company plans first-in-human trials of IBIO-610 in the first half of 2027; results in NHPs may not replicate in humans.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Muscle-preserving obesity combo data positions IBIO-610 as a GLP-1 adjunct play ahead of first-in-human trials in 2027."},"keyFigures":{"drugName":"IBIO-610","phaseOfTrial":"preclinical (non-human primate)","customDimensions":{"study_weeks":8,"nhp_half_life_days":33.2,"activin_e_reduction_week8":"97%","fat_share_of_weight_loss_combo":"93%","lean_mass_share_of_weight_loss_combo":"6%","fat_share_of_weight_loss_semaglutide_alone":"77%","lean_mass_share_of_weight_loss_semaglutide_alone":"22%"}},"quotedText":"In this NHP study, IBIO-610 delivered durable, near-complete inhibition of active Activin E, and when combined with semaglutide, nearly all observed weight loss came from fat.","namedEntities":{"people":[{"name":"Martin Brenner","role":"CEO and Chief Scientific Officer"}],"products":["IBIO-610","semaglutide"],"companies":[{"name":"iBio, Inc.","ticker":"IBIO"},{"name":"European Association for the Study of Diabetes (EASD)","relationship":"conference presenter venue"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Positive preclinical NHP data supporting the lead obesity asset IBIO-610 in combination with semaglutide, with first-in-human trials planned for H1 2027. Still preclinical, so not a binary event, but meaningful validation for the pipeline."},"tickerRelevance":{"others":[],"primary":"IBIO"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"positive preclinical data, no human trials yet","issuerAuthored":true,"retailFavoriteBoost":"obesity/GLP-1 theme has retail interest"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"iBio highlighted preclinical data showing IBIO-610, a potential first-in-class Activin E antibody, preserved lean mass in obese non-human primates when combined with semaglutide.\n\nIn the eight-week NHP study (n=6 per group), only 6% of weight lost with the combination was lean mass versus 22% with semaglutide alone; fat made up 93% of weight lost with the combination versus 77% with semaglutide alone.\n\nIBIO-610 also showed a 97% reduction in active serum Activin E and a 33.2-day NHP half-life, with a projected human half-life supporting twice-yearly dosing.\n\nThe company plans first-in-human trials of IBIO-610 in the first half of 2027; results in NHPs may not replicate in humans.","key_figures":{"drugName":"IBIO-610","phaseOfTrial":"preclinical (non-human primate)","customDimensions":{"study_weeks":8,"nhp_half_life_days":33.2,"activin_e_reduction_week8":"97%","fat_share_of_weight_loss_combo":"93%","lean_mass_share_of_weight_loss_combo":"6%","fat_share_of_weight_loss_semaglutide_alone":"77%","lean_mass_share_of_weight_loss_semaglutide_alone":"22%"}},"named_entities":{"people":[{"name":"Martin Brenner","role":"CEO and Chief Scientific Officer"}],"products":["IBIO-610","semaglutide"],"companies":[{"name":"iBio, Inc.","ticker":"IBIO"},{"name":"European Association for the Study of Diabetes (EASD)","relationship":"conference presenter venue"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T11:00:18.346Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"positive preclinical data, no human trials yet","issuerAuthored":true,"retailFavoriteBoost":"obesity/GLP-1 theme has retail interest"}},"durationMs":6110,"modelName":"glm-5.3-flashx"}}